Crosstalk between transforming growth factor β-2 and Autotaxin in trabecular meshwork and different subtypes of glaucoma.
Crosstalk between transforming growth factor β-2 and Autotaxin in trabecular meshwork and different subtypes of glaucoma.
复制标题
DOI:
10.1186/s12929-021-00745-3
复制
发表时间:
2021-06-17
影响因子:
11
通讯作者:
Aihara M
中科院分区:
文献类型:
--
作者:
Igarashi N;Honjo M;Yamagishi R;Kurano M;Yatomi Y;Igarashi K;Kaburaki T;Aihara M
Elevated transforming growth factor (TGF)-β2 in aqueous humor (AH) has been suggested to contribute to trabecular meshwork (TM) fibrosis and intraocular pressure (IOP) regulation in primary open-angle glaucoma (POAG), but TGF-β2 is downregulated in secondary open-angle glaucoma (SOAG). Because autotaxin (ATX) is upregulated in SOAG, we investigated the relationships and trans-signaling interactions of these mediators. The level of ATX in AH was determined using a two-site immunoenzymetric assay, and TGF-β levels were measured using the Bio-Plex Pro TGF-β Assay. RNA scope was used to assess the expression of ATX and TGF-β2 in human’s eye specimen. And in vitro studies were performed using hTM cells to explore if trans-signaling of TGF-β2 regulates ATX expressions. TGF-β2/ATX ratio was significantly high in AH of control or POAG compared with SOAG, and negatively correlated with IOP. RNA scope revelated positive expressions of both TGF-β2 and ATX in ciliary body (CB) and TM in control, but ATX expressions was significantly enhanced in SOAG. In hTM cells, ATX expressions were regulated by TGF-β2 with concentration-dependent manner. In counter, ATX also induced TGF-β1, TGF-β2 and TGFBI upregulations and activation of the Smad-sensitive promoter, as well as upregulation of fibrotic markers, and these upregulation was significantly suppressed by both TGF-β and ATX inhibition. Trans-signaling of TGF-β2 regulates ATX expressions and thereby induced upregulations of TGF-βs or fibrosis of hTM. TGF-β2 trans-signaling potently regulate ATX transcription and signaling in hTM cells, which may reflect different profile of these mediators in glaucoma subtypes. Trial Registration This prospective observational study was approved by the Institutional Review Board of the University of Tokyo and was registered with the University Hospital Medical Information Network Clinical Trials Registry of Japan (ID: UMIN000027137). All study procedures conformed to the Declaration of Helsinki. Written informed consent was obtained from each patient. The online version contains supplementary material available at 10.1186/s12929-021-00745-3.
登录
查看更多内容
影响因子:
4.8
作者:
Kanda Y
通讯作者:
Kanda Y
影响因子:
4.6
作者:
Igarashi N;Honjo M;Asaoka R;Kurano M;Yatomi Y;Igarashi K;Miyata K;Kaburaki T;Aihara M
通讯作者:
Aihara M
影响因子:
6.2
作者:
Bissey PA;Law JH;Bruce JP;Shi W;Renoult A;Chua MLK;Yip KW;Liu FF
通讯作者:
Liu FF
DOI:
10.1007/s004170000252
发表时间:
2001-03-01
影响因子:
2.7
作者:
Picht, G;Welge-Luessen, U;Lütjen-Drecoll, E
通讯作者:
Lütjen-Drecoll, E
影响因子:
6
作者:
Geng, Hui;Lan, Rongpei;Venkatachalam, Manjeri A.
通讯作者:
Venkatachalam, Manjeri A.